tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

JSPR Stock Latest News

Jasper Therapeutics announces common stock offering, no amount given
The FlyJasper Therapeutics announces common stock offering, no amount given
7h ago
JSPR
Jasper Therapeutics price target lowered to $25 from $29 at UBS
PremiumThe Fly
Jasper Therapeutics price target lowered to $25 from $29 at UBS
1M ago
JSPR
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
PremiumRatings
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
1M ago
JSPR
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
PremiumCompany Announcements
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
1M ago
JSPR
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
PremiumRatings
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
1M ago
JSPR
Jasper Therapeutics Reports Promising Q2 2025 Results
PremiumCompany AnnouncementsJasper Therapeutics Reports Promising Q2 2025 Results
1M ago
JSPR
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
Premium
The Fly
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
1M ago
JSPR
Jasper Therapeutics Announces Major Corporate Reorganization
Premium
Company Announcements
Jasper Therapeutics Announces Major Corporate Reorganization
2M ago
8K
JSPR
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
PremiumThe Fly
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
2M ago
JSPR
RBC downgrades Jasper Therapeutics on questions about briquilimab
PremiumThe Fly
RBC downgrades Jasper Therapeutics on questions about briquilimab
2M ago
CLDX
JSPR
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
PremiumThe Fly
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
2M ago
JSPR
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
2M ago
JSPR
Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
PremiumThe FlyJasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
2M ago
JSPR
Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
Premium
Ratings
Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
2M ago
JSPR
Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
Premium
The Fly
Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
2M ago
JSPR
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe Fly
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
2M ago
JSPR
Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile
PremiumRatings
Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile
2M ago
JSPR
Jasper Therapeutics price target lowered to $20 from $64 at BTIG
PremiumThe Fly
Jasper Therapeutics price target lowered to $20 from $64 at BTIG
2M ago
JSPR
Jasper Therapeutics downgraded to Market Perform at William Blair
PremiumThe Fly
Jasper Therapeutics downgraded to Market Perform at William Blair
2M ago
JSPR
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Efficacy and Resolved Trial Setbacks
PremiumRatingsBuy Rating Affirmed for Jasper Therapeutics Amid Promising Efficacy and Resolved Trial Setbacks
2M ago
JSPR
Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
Premium
The Fly
Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
2M ago
JSPR
Jasper Therapeutics Reports Promising Briquilimab Study Results
Premium
Company Announcements
Jasper Therapeutics Reports Promising Briquilimab Study Results
2M ago
8K
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >